GP management of osteoarthritic pain in Hong Kong

Australian Family Physician

Volumn 37, Issue 10, 2008, Pages 874-878

  Lee, Albert ^a   Tsang, Clement K K ^a   Siu, Hon Kei ^a   Wong, William Chi Wai ^b   Wong, Samuel Yeung Shan ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ARTICLE; ATTITUDE TO HEALTH; CROSS-SECTIONAL STUDY; GENERAL PRACTICE; HONG KONG; HUMAN; KINESIOTHERAPY; OSTEOARTHRITIS; PAIN; PATIENT EDUCATION; PHYSIOTHERAPY; QUESTIONNAIRE;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROSS-SECTIONAL STUDIES; CYCLOOXYGENASE 2 INHIBITORS; EXERCISE THERAPY; FAMILY PRACTICE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HONG KONG; HUMANS; OSTEOARTHRITIS; PAIN; PATIENT EDUCATION AS TOPIC; PHYSICAL THERAPY MODALITIES; QUESTIONNAIRES;

EID: 54349103338     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. United Nations Department of Economic Social Affair. World population prospects: the 2004 revision population database. Available at http://esa.un.org/unpp [Accessed 10 May 2006].
2. Lee A, Lau FL, Hazelett CB, et al. Morbidity pattern of non-urgent patients attending accident and emergency departments in Hong Kong: cross-sectional study. Hong Kong Med J 2001;7:131-8.
3. Lee A. Vioxx withdrawal marks important opportunity to review primary care management for for osteoarthritis. Hong Kong Med J 2005;11:135.
4. Lee A, Tsang KK, Wong WCW, Wong SYS. An evidence-based approach to managing osteoarthritis in the primary care setting. Hong Kong Practitioner 2004;26:457-8.
5. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55.
6. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis - report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-81.
7. [Anonymous]. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905-15.
8. Grainger R, Cicuttini FM. Medical management of osteoarthritis of the knee and hip joints. Med J Aust 2004;180:232-6.
9. Lee A, Tsang KK, Wong WCW, et al. Clinical guidelines for managing lower limb osteoarthritis in Hong Kong primary care setting, December 2004. Available at www.cuhk.edu.hk/med/hep/JPCPH/special_issue/Dec04.pdf [Accessed 15 Dec 2005].
10. Chevalier X, Marre JP, de Butler J, Hercek A. Questionnaire survey of management and prescription of general practitioners in knee osteoarthritis: a comparison with 2000 EULAR recommendations. Clin Exp Rheumatol 2004;22:205-12.
11. Wee CC, McCarthy EP, Davis RB, Philip RS. Physicians counselling about exercise. JAMA 1999; 282:1583-8.
12. Bull FC, Shipper EC, Jamorzik K, Blankshy BA. Beliefs and behaviour of general practitioners regarding promotion of physical activity. Aust J Public Health 1995;19:300-4.
13. Lisse JR, Perlman M, Johansson G, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med 2003;139:539-46.
14. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30:11-8.
15. Myllykangas-Luosujarvi R, Lu HS, Chen SL, et al. Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration. Scand J Rheumatol 2002;31:337-44.
16. Makarowski W, Zhao WW, Bevirt T, Recker DP. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthr Cartil 2002;10:290-6.
17. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med 1999;107:65S-70.
18. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999;66:76-84.
19. Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000;7:159-75.
20. Ruoff GE. The impact of nonsteroidal anti-inflammatory drugs on hypertension: alternative analgesics for patients at risk. Clin Ther 1998;20:376-87.
21. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999;106:13S-24.
22. [Anonymous]. Considerations for the safe prescribing and use of the COX-2-specific inhibitors. Med J Aust 2002;176:328-31.
23. March L, Irwig L, Schwarz J, Simpson J, Chock C, Brooks P. N of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis. BMJ 1994;309:1041-5.
24. Wegman AC, van der Windt DA, de Haan M, Deville WL, Fo CT, de Vries TP. Switching from NSAIDs to paracetamol: a series of n of 1 trials for individual patients with osteoarthritis. Ann Rheum Dis 2003;62:1156-61.